These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29354781)

  • 1. Suppression of Arrhythmia by Enhancing Mitochondrial Ca
    Schweitzer MK; Wilting F; Sedej S; Dreizehnter L; Dupper NJ; Tian Q; Moretti A; My I; Kwon O; Priori SG; Laugwitz KL; Storch U; Lipp P; Breit A; Mederos Y Schnitzler M; Gudermann T; Schredelseker J
    JACC Basic Transl Sci; 2017 Dec; 2(6):737-747. PubMed ID: 29354781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approved drugs ezetimibe and disulfiram enhance mitochondrial Ca
    Sander P; Feng M; Schweitzer MK; Wilting F; Gutenthaler SM; Arduino DM; Fischbach S; Dreizehnter L; Moretti A; Gudermann T; Perocchi F; Schredelseker J
    Br J Pharmacol; 2021 Nov; 178(22):4518-4532. PubMed ID: 34287836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation.
    Sedej S; Heinzel FR; Walther S; Dybkova N; Wakula P; Groborz J; Gronau P; Maier LS; Vos MA; Lai FA; Napolitano C; Priori SG; Kockskämper J; Pieske B
    Cardiovasc Res; 2010 Jul; 87(1):50-9. PubMed ID: 20080988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Gao J; Makiyama T; Yamamoto Y; Kobayashi T; Aoki H; Maurissen TL; Wuriyanghai Y; Kashiwa A; Imamura T; Aizawa T; Huang H; Kohjitani H; Nishikawa M; Chonabayashi K; Fukuyama M; Manabe H; Nakau K; Wada T; Kato K; Toyoda F; Yoshida Y; Makita N; Woltjen K; Ohno S; Kurebayashi N; Murayama T; Sakurai T; Horie M; Kimura T
    Circ Arrhythm Electrophysiol; 2023 Mar; 16(3):e011387. PubMed ID: 36866681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of RyR2 inhibitor EL20 in induced pluripotent stem cell-derived cardiomyocytes from a patient with catecholaminergic polymorphic ventricular tachycardia.
    Word TA; Quick AP; Miyake CY; Shak MK; Pan X; Kim JJ; Allen HD; Sibrian-Vazquez M; Strongin RM; Landstrom AP; Wehrens XHT
    J Cell Mol Med; 2021 Jun; 25(13):6115-24. PubMed ID: 34110090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Z16b, a natural compound from Ganoderma cochlear is a novel RyR2 stabilizer preventing catecholaminergic polymorphic ventricular tachycardia.
    Wan JF; Wang G; Qin FY; Huang DL; Wang Y; Su AL; Zhang HP; Liu Y; Zeng SY; Wei CL; Cheng YX; Liu J
    Acta Pharmacol Sin; 2022 Sep; 43(9):2340-2350. PubMed ID: 35190699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purkinje cells from RyR2 mutant mice are highly arrhythmogenic but responsive to targeted therapy.
    Kang G; Giovannone SF; Liu N; Liu FY; Zhang J; Priori SG; Fishman GI
    Circ Res; 2010 Aug; 107(4):512-9. PubMed ID: 20595652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia.
    Liu N; Ruan Y; Denegri M; Bachetti T; Li Y; Colombi B; Napolitano C; Coetzee WA; Priori SG
    J Mol Cell Cardiol; 2011 Jan; 50(1):214-22. PubMed ID: 20937285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
    Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC
    Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting intracellular calcium cycling in catecholaminergic polymorphic ventricular tachycardia: a theoretical investigation.
    Sung RJ; Lo CP; Hsiao PY; Tien HC
    Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1625-38. PubMed ID: 21742998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
    Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C
    Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical effect of increased diastolic Ca(2+) release and decreased sinoatrial node activity in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
    Neco P; Torrente AG; Mesirca P; Zorio E; Liu N; Priori SG; Napolitano C; Richard S; Benitah JP; Mangoni ME; Gómez AM
    Circulation; 2012 Jul; 126(4):392-401. PubMed ID: 22711277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Ca2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia.
    Fernández-Velasco M; Rueda A; Rizzi N; Benitah JP; Colombi B; Napolitano C; Priori SG; Richard S; Gómez AM
    Circ Res; 2009 Jan; 104(2):201-9, 12p following 209. PubMed ID: 19096022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload.
    Hwang HS; Baldo MP; Rodriguez JP; Faggioni M; Knollmann BC
    Front Physiol; 2019; 10():992. PubMed ID: 31456692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antiarrhythmic compound efsevin directly modulates voltage-dependent anion channel 2 by binding to its inner wall and enhancing mitochondrial Ca
    Wilting F; Kopp R; Gurnev PA; Schedel A; Dupper NJ; Kwon O; Nicke A; Gudermann T; Schredelseker J
    Br J Pharmacol; 2020 Jul; 177(13):2947-2958. PubMed ID: 32059260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiarrhythmic Effects of Carvedilol and Flecainide in Cardiomyocytes Derived from Catecholaminergic Polymorphic Ventricular Tachycardia Patients.
    Pölönen RP; Penttinen K; Swan H; Aalto-Setälä K
    Stem Cells Int; 2018; 2018():9109503. PubMed ID: 29760739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Liu B; Walton SD; Ho HT; Belevych AE; Tikunova SB; Bonilla I; Shettigar V; Knollmann BC; Priori SG; Volpe P; Radwański PB; Davis JP; Györke S
    J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29720499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.
    Jung CB; Moretti A; Mederos y Schnitzler M; Iop L; Storch U; Bellin M; Dorn T; Ruppenthal S; Pfeiffer S; Goedel A; Dirschinger RJ; Seyfarth M; Lam JT; Sinnecker D; Gudermann T; Lipp P; Laugwitz KL
    EMBO Mol Med; 2012 Mar; 4(3):180-91. PubMed ID: 22174035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model.
    Liu N; Colombi B; Memmi M; Zissimopoulos S; Rizzi N; Negri S; Imbriani M; Napolitano C; Lai FA; Priori SG
    Circ Res; 2006 Aug; 99(3):292-8. PubMed ID: 16825580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SR-Mitochondria Crosstalk Shapes Ca Signalling to Impact Pathophenotype in Disease Models Marked by Dysregulated Intracellular Ca Release.
    Tow BD; Deb A; Neupane S; Patel SM; Reed M; Loper AB; Eliseev RA; Knollmann BC; Györke S; Liu B
    Cardiovasc Res; 2022 Oct; 118(13):2819-2832. PubMed ID: 34677619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.